| Survival and prognostic factors in systemic sclerosis–associated pulmonary hypertension: a systematic review and meta‐analysis G Lefevre, L Dauchet, E Hachulla, D Montani, V Sobanski, M Lambert, ... Arthritis & Rheumatism 65 (9), 2412-2423, 2013 | 315 | 2013 |
| COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study J Avouac, E Drumez, E Hachulla, R Seror, S Georgin-Lavialle, ... The Lancet Rheumatology 3 (6), e419-e426, 2021 | 270 | 2021 |
| Pulmonary hypertension in systemic sclerosis: different phenotypes D Launay, V Sobanski, E Hachulla, M Humbert European respiratory review 26 (145), 2017 | 150 | 2017 |
| Phenotypes determined by cluster analysis and their survival in the prospective European scleroderma trials and research cohort of patients with systemic sclerosis V Sobanski, J Giovannelli, Y Allanore, G Riemekasten, P Airò, S Vettori, ... Arthritis & rheumatology 71 (9), 1553-1570, 2019 | 126 | 2019 |
| Prevalence of anti–RNA polymerase III antibodies in systemic sclerosis: new data from a French cohort and a systematic review and meta‐analysis V Sobanski, L Dauchet, G Lefevre, M Lambert, S Morell‐Dubois, T Sy, ... Arthritis & rheumatology 66 (2), 407-417, 2014 | 114 | 2014 |
| Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease N Le Gouellec, A Duhamel, T Perez, AL Hachulla, V Sobanski, JB Faivre, ... PLoS One 12 (8), e0181692, 2017 | 98 | 2017 |
| Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients FAI2R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors Annals of the Rheumatic Diseases 80 (4), 527-538, 2021 | 95 | 2021 |
| Characteristics and survival of anti–U1 RNP antibody–positive patients with connective tissue disease–associated pulmonary arterial hypertension V Sobanski, J Giovannelli, BM Lynch, BE Schreiber, SI Nihtyanova, ... Arthritis & rheumatology 68 (2), 484-493, 2016 | 95 | 2016 |
| Altered B lymphocyte homeostasis and functions in systemic sclerosis A Forestier, T Guerrier, M Jouvray, J Giovannelli, G Lefèvre, V Sobanski, ... Autoimmunity reviews 17 (3), 244-255, 2018 | 92 | 2018 |
| Pulmonary arterial hypertension associated with systemic lupus erythematosus: results from the French Pulmonary Hypertension Registry E Hachulla, X Jais, G Cinquetti, P Clerson, L Rottat, D Launay, V Cottin, ... Chest 153 (1), 143-151, 2018 | 90 | 2018 |
| French recommendations for the management of systemic sclerosis E Hachulla, C Agard, Y Allanore, J Avouac, B Bader-Meunier, A Belot, ... Orphanet Journal of Rare Diseases 16, 1-61, 2021 | 74 | 2021 |
| Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or … CM Yelnik, G Urbanski, E Drumez, V Sobanski, H Maillard, A Lanteri, ... Lupus 26 (2), 163-169, 2017 | 72 | 2017 |
| Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis D Launay, D Montani, PM Hassoun, V Cottin, J Le Pavec, P Clerson, ... PloS one 13 (5), e0197112, 2018 | 69 | 2018 |
| Role of B cells in the pathogenesis of systemic sclerosis S Sanges, T Guerrier, D Launay, G Lefèvre, M Labalette, A Forestier, ... La Revue de médecine interne 38 (2), 113-124, 2017 | 68 | 2017 |
| Current approaches to the treatment of systemic-sclerosis-associated pulmonary arterial hypertension (SSc-PAH) V Sobanski, D Launay, E Hachulla, M Humbert Current rheumatology reports 18, 1-14, 2016 | 60 | 2016 |
| Severe toxoplasmosis in immunocompetent hosts: be aware of atypical strains V Sobanski, D Ajzenberg, L Delhaes, N Bautin, N Just American journal of respiratory and critical care medicine 187 (10), 1143-1145, 2013 | 54 | 2013 |
| Effect of in vitro and in vivo anakinra on cytokines production in Schnitzler syndrome D Launay, V Dutoit-Lefevre, E Faure, O Robineau, C Hauspie, V Sobanski, ... PloS one 8 (3), e59327, 2013 | 52 | 2013 |
| Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: A Scleroderma Patient-centered Intervention … BD Thombs, L Kwakkenbos, RS Henry, ME Carrier, S Patten, S Harb, ... Journal of Psychosomatic Research 139, 110262, 2020 | 47 | 2020 |
| Serum free light chains of immunoglobulins as biomarkers for systemic sclerosis characteristics, activity and severity A Lanteri, V Sobanski, C Langlois, G Lefèvre, C Hauspie, S Sanges, ... Autoimmunity reviews 13 (9), 974-980, 2014 | 47 | 2014 |
| Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study VK Jaeger, M Tikly, D Xu, E Siegert, E Hachulla, P Airò, G Valentini, ... Rheumatology 59 (7), 1684-1694, 2020 | 45 | 2020 |
